Full Text View
Tabular View
No Study Results Posted
Related Studies
Once Daily 3TC, Efavirenz and ddI for HIV Infection
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by 407 Doctors.
Recruitment status was  Recruiting
Study NCT00214435   Information provided by 407 Doctors

First Received on September 16, 2005.   Last Updated on October 21, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infection
AIDS
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
HIV Infections
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Additional drug interventions recognized in this trial
Efavirenz
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
407 Doctors
Bristol-Myers Squibb
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services